This review proposes an integrative mechanistic framework in which age-related epigenetic and genomic changes influence both tumor biology and cfDNA composition, with transposable elements acting as a central link between aging and cancer in reproductive system malignancies.
Key Findings
Background
Aging is one of the strongest risk factors for reproductive system cancers, which are mainly diagnosed in older adults and often show different clinical and biological features compared with the same tumors in younger patients.
Cancers reviewed include ovarian, endometrial, cervical, vulvar, prostate, and penile cancers.
Older patients frequently present with frailty and multiple comorbidities that limit use of screening programs and invasive diagnostic procedures.
These factors often lead to delayed diagnosis and worse outcomes in older patients.
Background
Aging contributes to cancer development and progression through multiple biological mechanisms including hormonal changes, immune decline, epigenetic alterations, and accumulation of DNA damage.
These age-associated changes collectively promote the development and progression of reproductive system cancers.
The review describes how these aging-related biological processes are mirrored in cell-free DNA (cfDNA) profiles.
The authors frame these interconnected processes within an integrative mechanistic framework.
Background
Cell-free DNA (cfDNA) is identified as a minimally invasive biomarker obtainable from blood samples that provides molecular information on both tumor and host tissues in older and fragile patients.
cfDNA reflects tumor-specific alterations but is also influenced by aging-related changes in DNA release, fragmentation, and methylation.
The minimally invasive nature of cfDNA collection is particularly relevant for older patients who may not tolerate invasive diagnostic procedures.
The review focuses on the clinical use of cfDNA for cancer detection and monitoring specifically in older and fragile patients.
Discussion
Aging must be considered as a confounding variable when cfDNA-based biomarkers are applied in clinical practice, because aging independently alters cfDNA profiles.
Age-related changes in DNA release, fragmentation, and methylation all influence cfDNA composition independent of tumor-derived signals.
Failure to account for aging effects could confound interpretation of tumor-derived cfDNA signals.
The review explicitly states that 'aging must be considered when cfDNA-based biomarkers are applied in clinical practice.'
Results
Repetitive elements in cfDNA, including transposable elements, are strongly affected by both aging and tumor-related epigenetic changes and can be detected with high sensitivity even when the tumor fraction is low.
Special attention is given to repetitive elements in cfDNA as a category of biomarker.
The high sensitivity of transposable element detection even at low tumor fractions makes them particularly relevant for early or minimal-disease settings.
Transposable elements are proposed to act as a central mechanistic link between aging and cancer.
Conclusions
Transposable elements are proposed as a central link between aging and cancer within an integrative mechanistic framework connecting age-related epigenetic and genomic changes, tumor biology, and cfDNA composition.
The authors propose a novel integrative mechanistic framework specifically connecting these three domains.
Transposable elements undergo epigenetic dysregulation with both aging and tumor development, positioning them as a convergent node.
This framework is presented as a synthesis across reproductive system cancer types including ovarian, endometrial, cervical, vulvar, prostate, and penile cancers.
What This Means
This research suggests that the connection between aging and reproductive cancers (such as ovarian, endometrial, prostate, and related cancers) can be better understood by examining a type of biomarker found in blood called cell-free DNA (cfDNA). As people age, their cells release more DNA fragments into the bloodstream, and these fragments undergo chemical changes that are also seen in cancer. This means that a blood test analyzing cfDNA could potentially detect cancer earlier and more conveniently in elderly patients who may not be able to tolerate traditional invasive procedures like biopsies.
A particularly important finding from this review is that repetitive DNA sequences called transposable elements — sometimes called 'jumping genes' — appear to serve as a biological bridge between the aging process and cancer development. These elements are chemically silenced in healthy young tissue but become reactivated with aging and in tumors, leaving detectable signatures in the blood. Because they are abundant in the genome, their signals can be picked up in blood tests even when the amount of tumor DNA present is very small, making them especially promising for early detection.
This research suggests that doctors and researchers need to account for a patient's age when interpreting cfDNA blood tests for cancer, because aging itself changes the DNA patterns in blood independently of any tumor. The authors propose a unified framework explaining how aging, cancer biology, and blood-based DNA signals are all interconnected through these transposable elements, which could guide the development of more accurate, age-aware liquid biopsy tests for older cancer patients.
Cecati M, Vaiasicca S, Cianfruglia L, Fumarola S, Campagna R, Marchegiani F, et al.. (2026). Aging and Reproductive Cancers: An Integrative View on Cell-Free DNA and Transposable Elements.. Frontiers in bioscience (Landmark edition). https://doi.org/10.31083/FBL50970